Novogene(SH:688315)2025-02-26 10:50Financial Performance - Total operating revenue for 2024 reached RMB 2,111.32 million, a year-on-year increase of 5.45%[3] - Net profit attributable to shareholders of the parent company was RMB 1,944.48 million, reflecting a growth of 9.20% compared to the previous year[3] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 1,672.88 million, up 19.50% year-on-year[3] - Basic earnings per share rose to RMB 0.48, a 9.09% increase from the previous year[3] - The weighted average return on net assets decreased to 7.93%, down 0.55 percentage points from the previous year[3] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 36,366.04 million, an increase of 1.17% from the end of 2023[6] - Shareholders' equity attributable to the parent company was RMB 24,889.76 million, growing by 1.28% compared to the end of 2023[6] Strategic Initiatives - The company emphasized a strategy of total cost leadership and expanded overseas market presence to boost revenue[6] - Increased investment in new product and technology development to enhance innovation capabilities[6] Profitability Metrics - The company reported improvements in gross margin and profit margin, indicating enhanced profitability metrics[6]